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1 Leukocyte production of reactive oxygen species (ROS) is an essential component of the
antimicrobial armament mounted during host defense, but when released to the extracellular milieu
ROS can also injure host tissues and provoke inflammation. Polyisoprenyl phosphates (PIPPs) are
constituents of human leukocyte membranes that regulate pivotal intracellular enzymes, such as
phospholipase D (PLD). We prepared new PIPP mimetics and studied their impact in vivo on
leukocyte activation, including ROS generation, in acute inflammation.
2 In a stereospecific and concentration-dependent manner, the PIPP mimetics directly regulated
Streptomyces chromofuscus phospholipase D (sPLD) action. The IC50 for a (Z)-isomer of endogenous
presqualene diphosphate (PSDP) was 100 nM.
3 Structure–activity relationships were also determined for PIPP mimetic inhibition of recombinant
human PLD1b, a prominent isoform in human leukocytes. The PIPP mimetic rank order for PLD1b
inhibition differed from sPLD, although the (Z)-PSDP isomer remained the most potent PIPP mimetic
for inhibition of both enzymes. Truncation of PLD1b to its catalytic core uncovered potential
regulatory roles for both PSDP’s isoprenoid and diphosphate moieties.
4 The (Z)-PSDP isomer reduced ROS production by activated human leukocytes and decreased murine
neutrophil accumulation (65.6%) and ROS production (38.5%) in vivo during zymosan A-initiated
peritonitis. When administered intraperitoneally 2 h after zymosan A, the (Z)-PSDP isomer decreased in
vivo neutrophil accumulation (72.5%) and ROS generation (74.4%) 6 h later in peritoneal exudates.
5 Together, these results provide new means to protect and control unchecked inflammatory
responses that characterize many human diseases.
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Introduction
Innate immune responses to pathogens must be rapid to prevent
infection and reversible to avoid unintended tissue injury
(Nathan, 2002). Recent evidence has identified several, structu-
rally distinct classes of membrane-derived lipid mediators as
autacoid regulators of leukocyte functional responses in acute
inflammation (Gilroy et al., 2004). One of these involves
isoprenoid metabolism, which in addition to its fundamental
role in cholesterol biosynthesis, are also lipid mediators with an
important role in the regulation of host inflammatory
responses. These previously unappreciated roles of isoprenoids
are underscored by the hereditary periodic fever syndromes, as
many result from low isoprenoid levels secondary to defective
mevalonate kinase activity (Drenth & van der Meer, 2001;
Takada et al., 2003). Recently, polyisoprenyl phosphate (PIPP)
signaling, and specifically, the mevalonate-derived product
presqualene diphosphate (PSDP) was found to directly prevent
unwanted superoxide anion generation in human polymopho-
nuclear leukocytes (PMN) (Levy et al., 1997). Present in
leukocyte membranes, PSDP levels rapidly decline within
seconds of cell activation, unlocking regulatory enzymes, such
as phospholipase D (PLD), involved in PMN intracellular
signaling and cell activation as in NADPH oxidase assembly for
reactive oxygen species (ROS) generation (Levy et al., 1999a).
During host defense and inflammation, superoxide anions,
ozone, and other ROS are essential components in microbial
killing, yet also display potent cytotoxicity for host tissues
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(Wentworth et al., 2002; Babior et al., 2003). When
uncontrolled, ROS such as ozone can be violently toxic to
the host and appears to be linked to the pathobiology
of subacute inflammatory disorders, including a reversed
passive Arthus reaction in rat skin and human atherosclerosis
(Wentworth et al., 2002; 2003). Also, excess superoxide anions
and singlet oxygen radicals can have adverse consequences in
the lung and compromise the lung’s bactericidal activity
(Goldstein et al., 1971). Hence, rapid containment and
enzymatic regulation of endogenous ROS is required to
prevent oxidant-mediated damage to host tissues (Del Maestro
et al., 1980).
Biochemical events in PSDP signaling in human PMN raise
the possibility that PIPPs can serve as potent candidates that
can limit unwanted ROS production. To this end, novel
synthetic PIPP mimetics were prepared and assessed for their
potential impact in human leukocyte activation and murine
acute inflammation.
Methods
All experiments with mice (Charles River Laboratories,
Wilmington, MA, U.S.A.) were performed in accordance with
Institutional Guidelines for the Proper Care and Handling of
Experimental Animals. For zymosan A-initiated peritonitis,
mice were 6–8 weeks old, 20–25 g, FVB, male animals. Mice
were maintained on a light–dark cycle with light from 07:00 to
20:00 hours at 251C and fed with a standard laboratory diet
and water ad libitum.
PLD enzymatic activity
PLD activity was monitored by choline release from phos-
phatidyl choline (PC) as described earlier (Levy et al., 1999a).
Briefly, PC (25 mg ml1) was brought to dryness under a gentle
stream of N2, and liposomes were prepared in 50 mM Tris,
36 mM CaCl2, pH 7.4 by sonication. After warming (5 min,
301C), PC (final concentration 2 mM) was incubated (10 min,
301C) with Streptomyces chromofuscus PLD (sPLD) (2 units
per reaction, Sigma Chemical Co.) in the presence of authentic
PSDP, structurally related mimetics in a concentration rage of
1 nM to 1mM or vehicle (o0.1% ethanol). Reactions were
stopped with 1 M Tris, 50 mM EDTA, pH 8.0, and free choline
oxidized with horseradish peroxidase for detection by spectro-
photometer (Model 8453, Agilent) (Levy et al., 1999a).
For assessing recombinant human PLD1b activity, Sf9
insect cells confluent in a T175 flask were virally transfected
with full-length or truncated human PLD1b (Sung et al.,
1999). After 48 h, recombinant PLD was partially purified as
described earlier (Sung et al., 1999). Cells were pelleted (500 g,
10 min, 41C) and resuspended in iced 50 mM Tris, 36 mM
CaCl2, pH 7.4 prior to membrane disruption (Sonic Dismem-
brator, Fisher Scientific). Intracellular membranes were
pelleted (14,000 g, 10 min, 01C) and resuspended to 250–
500 mg protein ml1 to determine PLD activity as described
earlier (Levy et al., 1999a; Sung et al., 1999).
Generation of ROS by human leukocytes
For human PMN, peripheral venous blood (B120 ml) was
obtained by venipuncture from healthy volunteers who denied
taking any medication for at least 2 weeks and had given
written informed consent to a protocol approved by Brigham
and Women’s Hospital’s Human Research Committee. PMN
were freshly isolated from whole blood as described earlier
(Levy et al., 1999b) and suspended (7.5 106 PMN ml1, 371C)
in phosphate-buffered saline (pH 7.45) with CaCl2 and MgCl2
(1 mM). ROS generation in vitro was determined by continu-
ously monitoring oxidation of indigo carmine (50 mM) to isatin
sulfonic acid at 610 nm at 5 s intervals while immersed in a
continuously flowing water bath-jacketed cassette (371C) or
after timed incubations (10 min, 371C) in the presence of an
agonist (i.e., 0.1mM PMA) or vehicle (o0.1% ethanol).
Zymosan A-initiated peritonitis
PSDP or structurally related compounds (0–5 nmol in 0.1 ml
0.9% sterile saline) were delivered intraperitoneally (i.p.)
within the same syringe, after warming to 371C, with zymosan
A (0.9 mg in 0.9 ml 0.9% sterile saline). After 2 h, animals were
anesthetized with isoflurane (Abbott Laboratories, North
Chicago, IL, U.S.A.) and, while still alive, indigo carmine
(5 ml of 50mM solution in phosphate-buffered saline) was
injected (i.p.). Elicited leukocytes in the peritoneal lavage were
collected. Total and differential leukocytes were enumerated
in the exudate cell pellets (Bannenberg et al., 2005). Superoxide
and particularly ROS and ozone formation in vivo in the
peritoneal exudates were determined in the cell-free super-
natant (800 g, 5 min) by the conversion of indigo carmine to
isatin sulfonic acid that led to decrements in absorbance at
610 nm relative to that obtained with the initial materials
(Wentworth et al., 2002; Kettle et al., 2004).
Molecular modeling of PSDP and PLD
Modeling was performed and carried out with manual
positioning using O (Jones, version 8.0, Uppsala, Sweden)
for the complex of PSDP and PLD from Streptomyces sp.
Strain PMF (PDB accession #1F0I) (Leiros et al., 2000).
Residues numbered 382–389 (labeled in Figure 4) are not
visible in the crystal structure.
Materials
Phosphatidylcholine (PC, C10 : 0) was purchased from Avanti
Polar Lipids (Alabaster, AL, U.S.A.), and sPLD, choline
oxidase, horseradish peroxidase, indigo carmine, PMA, and
zymosan A were obtained from Sigma Chemical Co. (St Louis,
MO, U.S.A.). Sf9 cells were from BD Pharmingen (San Jose,
CA, U.S.A.). Authentic PSDP, PSMP, and their structural
mimetics were prepared by total synthesis in stereochemically




prepared as described earlier by Poulter and co-workers
(Rogers et al., 1995). The (Z)-isomers were prepared using
similar methods. (Z)-PS-CO2Me was separated from its (E)-
isomer and its spectroscopic data matched those reported
earlier (Rogers et al., 1995). The conversion of isomerically
pure (Z)-PS-CO2Me to (Z)-PSMP and (Z)-PSDP was per-
formed similarly to the synthesis of the (E)-isomers as described
earlier (Rogers et al., 1995). All compounds were characterized
by NMR spectroscopy and gave satisfactory data.
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Statistical analysis
Results are expressed as mean7s.e. Statistical significance of
differences was assessed by Student’s t-test for comparison of
two samples. Po0.05 was set as the level of significance.
Results
Structure–activity relationships for PLD inhibition
by new PIPP mimetics
In PMN, PLD action is an essential component in the
activation of the NADPH oxidase required for ROS produc-
tion (Agwu et al., 1991). We synthesized a series of PSDP
mimetics (Figure 1a) that preserved distinct structural elements
(i.e., isoprenoid backbone, stereochemistry, cyclopropylcarbi-
nyl ring, or phosphates) to identify those features pivotal to
PLD inhibition. Purified bacterial PLD from Streptomyces
chromofuscus (sPLD) was significantly inhibited by native, (E)-
PSDP (Figure 1b). Of interest, a synthetic (E)-PSDP mimetic
devoid of phosphates ((E)-PS-CO2Me) displayed similar
inhibition (B60%). In contrast, shielding of either (E)-PSMP
or (E)-PSDP by tetra-butyl ammonium groups prevented
inhibition of sPLD (Figure 1b). Together, these results suggest
that the isoprenoid backbone of PSDP possesses sPLD
regulatory activity.
A change in alkene bond geometry from (E) to (Z)
(Figure 1a) markedly enhanced inhibition of sPLD by both
the monophosphate and diphosphate (Z)-isomers. However,
these modifications did not significantly alter the inhibitory
capacity of the carboxy methyl ester (Figure 1c). It is
Figure 1 Structure–activity relationship for new PIPP mimetics and PLD inhibition. (a) Synthetic mimetics of native PSDP were
prepared to determine the impact of stereoselectivity on its biological actions. (b) The impact of phosphate removal or shielding (via
tetra-butyl ammonium ((nBu)4Nþ )) and (c) isoprenoid stereochemistry was determined for inhibition of sPLD (2 units per
reaction) by native PSDP or structural isomer (1 mM) (see Methods). Values are the mean7s.e.m. for n¼ 6. *Po0.05 by Student’s
t-test for (b) isolated sPLD inhibition and (c) difference between (Z)- and (E)-isomers. (d) Concentration-dependent inhibition
of sPLD activity by (Z)-PSDP and (Z)-PSMP isomers. Mean7s.e.m. for n¼ 3.
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noteworthy that endogenous PSDP carries this isoprenoid unit
in the (E) configuration (Figure 1a). The inhibition of PLD
by (Z)-PSDP and (Z)-PSMP was significantly greater than
that observed for either the (E)-PSDP or (E)-PSMP mimetics
(n¼ 6, Po0.05). PLD inhibition by (Z)-PSDP and (Z)-PSMP
was concentration-dependent in the nM range (Figure 1d). The
half maximal sPLD inhibition with PSDP at 100 nM gave an
apparent B2 : 1 PSDP : sPLD relationship. These results point
to the contributions of the isoprenoid chains as well as indicate
an additional site of interaction for the diphosphate in the
regulation of PLD.
In human PMN, PLD1b is a prominent isoform that
accumulates at phagosomal membranes upon cell activation
(Cadwallader et al., 2004), and native PSDP is a potent
inhibitor of recombinant human PLD1b (Levy et al., 1999a).
Thus, we next utilized the new mimetics to assess the potential
site(s) of interaction for PSDP within this isolated mammalian
PLD. To this end, recombinant full-length human PLD1b
as well as a truncated form of hPLD1b were expressed for
incubations with the PSDP mimetics (Figure 2a). The
truncated hPLD1b (D1–325, D505–621) carries the carboxy-
terminal domain (CT) and four highly conserved domains
(CRI-IV) in bacterial and mammalian PLDs essential for
catalysis (Sung et al., 1999), but select regulatory sites, such as
PX and PH-like domains that can interact with phosphory-
lated lipids (Stahelin et al., 2004), are not present. Full-length
human PLD1b was significantly inhibited by native PSDP
(1 mM). At equimolar amounts, the rank-order potency was
native (E)-PSDP4(Z)-PSDP4(Z)-PSMP4(E)-PS-CO2Me
(Figure 2b). The low activity of (E)-PS-CO2Me for rhPLD1b
was distinct from that observed with sPLD (Figure 1c),
emphasizing the importance of the diphosphate in PSDP’s
inhibition of PLD1b. Of note, the activity of (Z)-PSDP was
markedly decreased by truncation of PLD1b, but the
inhibitory properties of the (E)-containing native PSDP
and its carboxy methyl ester for PC hydrolysis were
not substantially changed by truncation of the enzyme
(Figure 2b). Hence, native, (E)-PSDP can directly inhibit both
(D1–325, D505–621)-hPLD1b and sPLD, which are similar in
size and share homologous CR domains. The (Z)-PSDP and
(Z)-PSMP isomers each lose activity for (D1–325, D505–621)-
hPLD1b, suggesting the presence of additional regulatory
site(s) in hPLD1b that are outside the enzyme’s catalytic
center.
Synthetic PIPP mimetics regulate inflammatory ROS
To determine whether the new PSDP mimetics had direct
actions on leukocyte ROS generation, we monitored conver-
sion in vitro of indigo carmine to isatin sulfonic acid during
human PMN activation (Figure 3a, inset). When freshly
isolated human PMN were activated with phorbol myristate
acetate (PMA, 107 M) in the presence of native, (E)-PSDP or
the new (Z)-PSDP isomer (1 mM), ROS production was
markedly reduced (Figure 3a). (Z)-PSDP decreased the initial
rate (20–90 s) of ROS generation from 33.8 to 10.0 pmol s1
(Figure 3a), suggesting inhibition of NADPH oxidase
assembly.
With decreased ROS generation by activated PMN in the
presence of (Z)-PSDP, we next determined if this PSDP
mimetic could regulate leukocyte activation in vivo in response
to a microbial phagocytic stimulus, yeast zymosan A, that was
given (i.p.) to mice to induce acute peritonitis (Figure 3b).
Shortly after instillation of zymosan A, activated PMN
respond (Bannenberg et al., 2005) and, here, within 2 h after
administration of zymosan A, there was substantial PMN
accumulation and ROS generation (8.0170.96 nmol ROS) in
peritoneal exudates (mean7s.e., n¼ 6) (Figure 3c). Native
PSDP or the (Z)-PSDP isomer, when given (i.p.) with zymosan
A, potently inhibited both PMN tissue accumulation and ROS
formation. The PIPP mimetic (1 nmol) gave 65.6 and 38.5%
inhibition, respectively (n¼ 6, Po0.05) (Figure 3c). For direct
comparison between in vitro and in vivo PIPP mimetic activity,
the least active mimetic in vitro for rhPLD1b inhibition, (E)-
PS-CO2Me, was also administered (i.p.) with zymosan A and
peritoneal inflammatory responses were monitored. At con-
centrations equimolar to native PSDP and (Z)-PSDP, this
relatively inactive compound in vitro did not significantly
block either ROS generation or leukocyte infiltration in vivo
(n¼ 3, Figure 3c). These findings indicate that the in vitro
structure–function relationship for PSDP and these PIPP
mimetics, (Z)-PSDP and (E)-PS-CO2Me, was retained in vivo.
To further explore the pharmacological effects of PSDP, we
administered native PSDP or the (Z)-PSDP isomer (i.p.) after
acute peritoneal inflammation was initiated (i.e., 2 h after
zymosan A administration). To determine if these compounds
dampen the immune response and promote resolution, we
monitored leukocyte trafficking into the peritoneal exudates
6 h after PSDP, PIPP isomer, or vehicle administration. Both
PSDP and (Z)-PSDP led to decrements of PMN numbers (66.0
and 72.5% inhibition, respectively) without significant change
in the number of either macrophages or lymphocytes (Table 1).
Figure 2 Structure–activity relationship for human PLD inhibition
by PIPP mimetics. (a) Full-length (FL) and truncated (Tr) PLD1b
were expressed in Sf9 cells. The truncated version of PLD1b lacked
amino acids 1–325 and 505–621, regions containing PX (83–209),
PH-like (222–330), and loop regulatory (505–620) domains. (b)
After partial purification, PLD activity was monitored in the
presence of select PIPP mimetics (1 mM) (see Methods). Values are
the mean7s.e.m. for n¼ 5. *Po0.05 by Student’s t-test for PLD
inhibition and **Po0.05 for the difference between truncated and
full-length rhPLD1b.
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Figure 3 PSDP regulates neutrophil-initiated ROS generation and inflammation. (a) ROS generation was measured by oxidation
of indigo carmine to isatin sulfonic acid (inset) when freshly isolated human PMN (7.5 106 ml1) were activated by exposure to
phorbol ester (PMA 107 M, 371C) in the absence or presence of (Z)-PSDP (1 mM). The calculated rate of change in absorbance at
610 nm is shown at baseline (prior to addition of the agonist), for the initial rate (t¼ 20–90 s) and for a subsequent 150 s. Reactions
are representative of n¼ 7. (b) Murine peritonitis was initiated by injection of zymosan A (0.9 mg, i.p) and elicited PMN
accumulation and in vivo oxidation of indigo carmine (decrements in absorbance at 610 nm) were determined 2 h later in peritoneal
exudates. (c) The native (E)-PSDP, (Z)-PSDP, or (E)-PS-CO2Me isomer (1 nmol) or vehicle (0.9% sterile saline) was instilled (i.p.) in
the same syringe as zymosan A. Values are for the mean7s.e.m. for nX3. *Po0.05 by Student’s t-test for a difference with PIPP
mimetic.
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In these in vivo experiments, the (Z)-PSDP isomer was
more potent than native PSDP for inhibition of PMN
trafficking and ROS generation (Table 1). These findings
indicate that PSDP and a structurally related isomer decreased
the acute inflammatory response without accelerating
leukocyte class switching at this time point. Together, these
results indicate that PSDP and select PIPP mimetics have the
capacity to directly regulate PMN activation in vitro and
in vivo and modulate the host response to peritoneal microbial
challenge.
Discussion and conclusions
To establish the functional determinants in PSDP’s direct
interactions with PLD, we designed a series of structurally
related compounds to probe the contribution of the isoprenoid
backbone, phosphates, and stereochemistry of native PSDP.
We assessed the role of the diphosphate in PLD inhibition by
replacing it with a carboxy methyl ester group (CO2Me), or the
anionic phosphates were shielded with tetra-butyl ammonium
groups. The results indicated that in the absence of both
phosphates, the isoprenoid backbone alone could also inhibit
sPLD, but not recombinant human PLD1b. To further
evaluate the role of the isoprenoid backbone, we changed the
configuration of the longer isoprenoid chains by switching the
geometry of the C¼C bond connected to the cyclopropyl ring
from the (E)- to the (Z)-orientation. This change in stereo-
chemistry and resulting conformational change markedly
enhanced sPLD inhibition to levels observed with native
PSDP. Recombinant human PLD1b activity was also blocked
by native PSDP and the (Z)-PIPP mimetics. Of interest,
truncation of PLD1b to primarily its’ catalytic domains
markedly altered the structure–activity relationships for the
compounds with a loss of potency for (Z)-PSDP as an
inhibitor that was not shared by (E)-PSDP. Together, these
findings indicate both a direct interaction between PLD and
the diphosphate present in PSDP and another interaction
domain in PLD present in both the bacterial and mammalian
forms of the enzyme for the (Z)-isoprenoid structure,
implicating at least two distinct sites of interaction for
inhibition of PLD by PSDP.
The PLD superfamily of enzymes shares the ability to bind
a phosphodiester moiety in their catalytic center. Streptomyces
sp. strain PMF PLD contains duplicated sequence motifs
HXK(X)4D required for catalytic activity that are in close
contact with the phospholipid phosphate head group (Leiros
et al., 2000). Structural comparison of this PLD to other
microbial PLDs and human PLD1b is most notable for
conservation of the two HKD motifs, which are related by a
pseudo-two-fold rotation axis running through the active-site-
bound phosphate. The catalytic center is deeply buried in the
protein, and the entrance to the substrate-binding pocket
appears shielded by two hydrophobic loops that are held to be
responsible for PLD’s membrane association (Leiros et al.,
2000). Figure 4 depicts a structural model for PSDP in relation
to the enzyme’s catalytic center. PSDP and the related active
compounds are of the appropriate size and shape to block
entry of PLD’s substrate, namely PC. This depiction is
consistent with both PSDP being a competitive inhibitor
of the enzyme (Levy et al., 1999a) and the presence of a
phosphate-coordinating center composed of histidine, lysine,
and asparagine residues of the HKD motifs. The (Z)-PSDP
isomer also fits in the substrate’s catalytic center, thereby
providing a reasonable mechanism for inhibition of PLD-
initiated formation of ROS during inflammation. Since a
complete crystal structure is not yet available for human PLD,
the present modeling was carried out with the Streptomyces sp.
strain PMF PLD structure (Leiros et al., 2000) that, like
hPLD1b, contains HKD motifs. Although sPLD and
Table 1 Delayed addition of polyisoprenyl phosphates dampens acute peritoneal inflammationa
Total leukocytes Neutrophils Macrophages Lymphocytes ROS generation
(percent inhibition)
Zymosan A 19.775.0 15.374.1 2.670.5 1.370.5
(Z)-PSDP 7.373.8* 4.273.8* 2.670.2 0.570.1 74.4*
Native PSDP 9.573.8 5.273.3 3.570.7 0.870.3 27.2
aNative PSDP, (Z)-PSDP, or vehicle was added 2 h after acute peritoneal inflammation was initiated by administration of zymosan A.
After 6 h, peritoneal exudates were obtained and leukocyte counts determined (see Methods). Values represent the mean and s.e.m. for
nX4 animals. *Po0.05 by Student’s t-test.
Figure 4 Interactions between PSDP and PLD. Modeling of native
PSDP in the active site of PLD (PDB accession # 1F0I) is based on
structural alignment of phosphate within the crystal structure and
the beta-phosphate of PSDP (see Methods). Hypothetical position
of isoprenoid moiety is based on the corresponding hydrophobic
regions of PLD interaction with the hydrophobic regions of PSDP.
The red arrow marks the alkene bond (in yellow) of PSDP
synthesized as (Z) or (E) for the PSDP mimetics used in the present
experiments. The inset shows the complex rotated 90 degrees. The
amino terminus (N) and carboxy terminus (C) are indicated. For
PSDP, carbon atoms are green, phosphate atoms red, and oxygen
atoms white.
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rhPLD1b have similar catalytic mechanisms, their sequences
outside the HKD motifs share little homology, likely account-
ing for the difference in the structure–activity relationship for
PSDP and the PIPP mimetics with these two PLD enzymes
(Figures 1c and 2b). Interaction sites with the human enzyme
outside the HKD motifs are not excluded because the human
enzyme is known to interact with Rho low molecular weight
GTP-binding proteins (Bowman et al., 1993) that are subject
to potential regulation by isoprenoid compounds.
Human PMN are coated with antibody, and when activated
generate substantial amounts of singlet oxygen (Steinbeck
et al., 1992) and oxidants with the chemical signature of ozone
(Wentworth et al., 2002). Activation of isolated human PMN
initiated ROS formation that was blocked by the addition of
native, (E)-PSDP as well as the new (Z)-PSDP mimetic in vitro.
These results indicate that PMN are one of the direct targets
for PSDP’s inhibition in its protective impact in peritonitis. By
reducing superoxide anion, ozone, and other ROS formation
in peritonitis, the PSDP mimetic dampened the amplitude of
the acute inflammatory response and lessened risk for
‘bystander’ injury of host abdominal tissues.
Acute inflammatory responses to pathogens or injury
characterize several prevalent clinical disorders, including
peritonitis (Winyard et al., 2003). Bacterial infection or
surgical injury during laparatomy commonly results in acute
peritoneal inflammation. Abdominal tissues can be subject to
unwanted injury by activated leukocytes, leading to fibrinous
intestinal adhesions that can entrap the bowel as well as other
unwanted sequellae (Ray et al., 1998). To assess whether
leukocyte-generated ROS in vivo is regulated by the PSDP
mimetics during peritonitis, we administered yeast zymosan A
into mouse peritoneum. This microbial cell wall component
stimulates leukocyte Toll-like receptor signaling (Beutler,
2002), phagocytosis (Getting et al., 1997), and here triggered
peritonitis with leukocyte infiltration and marked in vivo ROS
generation. In addition to the pivotal roles that cytokines and
chemokines play in inflammation and sepsis, lipid mediators,
such as leukotriene B4, also serve critical roles in leukocyte
recruitment and activation (Bannenberg et al., 2005). More-
over, leukotriene B4 initiates human PMN PSDP remodeling
within seconds in a temporal manner that is concomitant with
PLD activation and NADPH oxidase assembly – a process
that is inhibitable by lipoxin A4, which blocks PMN PSDP
turnover (Levy et al., 1999a). Local administration of a new
PSDP mimetic at low levels in vivo blocked zymosan A-
initiated leukocyte accumulation and ROS formation. Hence,
this new synthetic (Z)-containing isomer of PSDP (denoted
(Z)-PSDP) can serve as a potent inhibitor of PMN accumula-
tion and activation, displaying a 50% inhibitory concentration
at B1 nmol, similar in experimental peritonitis to that of the
common nonsteroidal anti-inflammatory drug indomethacin
(IC50 B0.5 nmol) (Kaplan et al., 1984).
Genetic defects in the PMN NADPH oxidase result in
chronic granulomatous disease in which reduced ROS
production leads to ineffective microbial clearance (Klebanoff,
1980). While chronic granulomatous disease highlights the
importance of this PMN response in infection, there are
several other human diseases stemming from overexuberant
inflammation (Weiss, 1989) and leukocyte release of anti-
microbial effectors, such as ROS, that are unwanted and toxic
to host tissues (Wentworth et al., 2003). In addition, aberrant
isoprenoid chemical signaling events are linked to unregulated
inflammation in several human periodic fever syndromes
(Drenth & van der Meer, 2001; Takada et al., 2003). Most
of these illnesses are without specific disease-remitting therapy.
Here, administration of a PSDP mimetic reduced peritoneal
leukocyte recruitment and activation in response to microbial
stimuli. The ability of PSDP and structurally related mimetics
to dampen leukocyte-driven ROS generation in vivo during
inflammation, as demonstrated here, can provide new mechan-
isms for protection from oxidant-mediated tissue injury and
toward controlling unchecked inflammatory responses.
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